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INTRODUCTION
•  Patients with Hemophilia A or B of all severities are at increased 
bleeding risk following injury of any origin.
•  A surgical intervention may be elective or of an emergency nature. 
It can be major or minor, according to the perceived or proven 
bleeding risk.
•  When planning a potentially dangerous procedure, we should 
consider the risks and benefits and very carefully take into 
account the patient’s age, life expectancy and immunologic status.
•  The patient should be managed in a hemophilia centre, where 
a comprehensive team approach can be provided. 
•  The aim of our study is to get a general view on all surgeries 




•  Hospital patient’s medical records where reviewed from January 
2006 to October 2010. 
•  Data collected on: age, type of hemophilia, surgical procedure, 
n.º of hospitalization days, hemostatic outcome, adverse events 
and other complications.
CONCLUSIONS
•  Hemophilia is not a contraindication for surgery, but adequate 
clotting factor correction is required. 
•  Factor dose and duration of replacement therapy depend 
on the type of intervention and severity of hemophilia.
•  21 patients (4 with inhibitor) underwent 24 surgeries 
(15 major and 9 minor) since 2006.
•  Overall hemostatic outcome was very good.
•  Patient 8 had an hemoperitoneum at day 4 and was submitted 
to laparoscopic revision; patients 10 and 20 developed a suture 
hematoma. 
•  The hemophiliac patient with inhibitor is at higher risk for 
management of bleeding control. Patient 13 needed sequential 
bypassing therapy. 
•  Despite the economic impact and need for Hospital’s Clinical 
Board approval, a rising number of elective surgeries in the inhibitor 
subpopulation are being performed, resulting in a better quality 
of life.
•  Weight control in the hemophiliac patient is crucial not only to 
prevent other medical associated diseases and joint damage 
but also for reducing the cost of treatment.
•  No thromboembolic adverse events were reported. 
RESULTS
•  21 patients identified 
•  Median age at surgery: 43 years-old (9-68)
•  Patients are caracterized according to the type of Hemophila in Table 1
•  24 surgeries: 15 major and 9 minor (Table 2)
•  pd FVIII/FIX concentrates were used in 16 procedures and rFVIII/FIX concentrates were used in 4. 
All administrations were in bolus
* aCCP; **inhibitor at day 10; ‡ urosepsis at day 14, transfered to ICU and died 3 months latter (patient w/ Diabetes Mellitus type 2).
Type of Hemophila Number of patients (21)
















1 A Knee arthroplasty 123000 21 Excellent  –
2 A Knee arthroplasty 118000 19 Excellent –
3 A Herniotomy 28000 10 Excellent –
4 A Hemorrhoidectomy 45000 7 Excellent –
5 A Knee arthroplasty 45000 8 Excellent –
6 A Knee arthroplasty 92000 18 Good –
7 A Radical prostatectomy 79500  57000* 14 Good
Inhibitor** 
Urosepsis‡
8 A Apendicectomy 70500 14 Good –
9 A Open femur reduction 55000 15 Excellent –
10 B Hydrocel 155000 18 Good –
11 B Thigh skin graft 185000 14 Excellent –









12 A Laparoscopic colecistectomy 287* 7 Excellent  –
13 A Apendicectomy with segmentar ileotomy 898*/156000° 26 Good –
14 A Apendicectomy 125000° 13 Good –
15 A Total nephrectomy 660* 17 Good –









16 A Tonsilectomy with adenoidectomy 65000 5 Excellent  –
17 A Multiple dental  extractions 3000 0 Excellent –









18 A Femur osteotomy 17000 11 Good –
19 A Multiple dental extractions 22000 4 Excellent –














Major 15 11 4
Minor 9 8 1
Table 1
Table 3 – Major surgical procedures in HA and HB patients:
Table 4 – Major surgery in patients with inhibitor:
Table 5 – Minor surgical procedures in HA and HB patients:
Table 2
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